Differences in prognosis by p53 expression after neoadjuvant chemotherapy in triple-negative breast cancer
- Authors
- Bae, Soo Youn; Lee, Jeong Hyeon; Bae, Jeoung Won; Jung, Seung Pil
- Issue Date
- Jun-2020
- Publisher
- 대한외과학회
- Keywords
- Immunohistochemistry; Neoadjuvant therapy; Prognosis; Triple negative breast neoplasms; Tumor suppressor potein p53
- Citation
- Annals of Surgical Treatment and Research, v.98, no.6, pp 291 - 298
- Pages
- 8
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- Annals of Surgical Treatment and Research
- Volume
- 98
- Number
- 6
- Start Page
- 291
- End Page
- 298
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/28090
- DOI
- 10.4174/astr.2020.98.6.291
- ISSN
- 2288-6575
2288-6796
- Abstract
- Purpose: Our previous studies suggested that p53-positive triple-negative breast cancer (TNBC) should be more sensitive to chemotherapy than p53-negative TNBC. The aim of this study was to determine whether p53 expression in TNBC could predict response to neoadjuvant chemotherapy and the resulting prognosis. Methods: From January 2009 to December 2017, TNBC patients who underwent neoadjuvant chemotherapy were reviewed, including a total of 31 TNBC patients who had clinical lymph node metastasis. The status of p53 expression in patients before and after chemotherapy was evaluated. Results: Two patients (22.2%, 2 of 9) achieved pCR in p53(+) TNBC and 4 patients (50%, 5 of 10) achieved pCR in p53(-) TNBC. There was no correlation between pCR rate and p53 expression (P = 0.350). Based on prechemotherapy p53 expression, there was no significant difference in disease-free survival (DFS) between p53(+) TNBC and p53(-) TNBC (P = 0.335). However, after chemotherapy, p53(+) TNBC had shown higher DFS than p53(-) TBNC (P = 0.099). Based on prechemotherapy p53 expression, p53(+) TNBC had better overall survival (OS) than p53(-) TNBC, but the difference was not statistically significant (P = 0.082). After chemotherapy, p53(+) TNBC showed significantly better OS than p53(-) TNBC (P = 0.018). Conclusion: Immunohistochemically detected p53 expression in TNBC could not predict the response to neoadjuvant chemotherapy. However, p53(+) TNBC had a better OS than p53(-) TNBC in patients who underwent neoadjuvant chemotherapy.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Pathology > 1. Journal Articles
- 2. Clinical Science > Department of Anesthesiology and Pain Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.